Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.
Coronary heart disease remains the leading cause of death in the United States. Although coronary heart disease and stroke entail very expensive therapies and extensive hospital utilization, the cost of preventive measures is also quite expensive. In this review, the factors that determine the cost-effectiveness of statin therapy for the primary and secondary prevention of coronary heart disease are discussed. A risk-based strategy for the selection of patients seems to provide cost-effective utilization of this potent treatment strategy. Appropriate patient selection should be accompanied by aggressive measures to improve utilization and compliance through improved physician and patient education.
Rockson
S G
SG
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. srockson@cvmed.stanford.edu
D003327:Coronary Disease / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics* / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000191:economics*
D000960:Hypolipidemic Agents